{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:58:30Z","timestamp":1771887510379,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T00:00:00Z","timestamp":1719532800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,28]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Multiple myeloma (MM) with extramedullary disease (EMD) is rare in clinical practice, and B cell maturation antigen (BCMA) CAR-T cell therapy is a novel therapy for hematologic malignancies. Very few reports have been published on the effect of CAR-T-cell therapy in MM with EMD. Here, we report a case of MM with extramedullary lesions treated with BCMA CAR-T therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>A 66-year-old female patient presented to our hospital with an enlarged left maxillary gingiva.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>Diagnosis of indolent MM stage III (DS staging) and stage III (ISS and R ISS) with extramedullary lesions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Intervention:<\/jats:title>\n                    <jats:p>The patient underwent a clinical trial of humanized anti-BCMA CAR T cell therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Symptoms improved; left gingival hyperplasia and swelling resolved; left buccal mass resolved; and neck and submandibular masses resolved. Pathological examination of the exfoliated masses showed necrotic tissue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>MM with extramedullary lesions often has limited treatment options, and traditional chemotherapy methods are ineffective; however, BCMA CAR-T cell therapy can significantly improve the symptoms of extramedullary lesions in MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000038541","type":"journal-article","created":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T14:48:29Z","timestamp":1719586109000},"page":"e38541","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Anti-BCMA CAR-T therapy for multiple myeloma with extramedullary disease: A case report and review of the literature"],"prefix":"10.1097","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3266-1977","authenticated-orcid":false,"given":"Huihui","family":"Shi","sequence":"first","affiliation":[{"name":"Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Zhang","sequence":"additional","affiliation":[{"name":"Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajing","family":"Su","sequence":"additional","affiliation":[{"name":"Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingwen","family":"Liu","sequence":"additional","affiliation":[{"name":"Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayuan","family":"Guo","sequence":"additional","affiliation":[{"name":"Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Hrain Biotechnology Co. Ltd., Shanghai, P.R. China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuling","family":"Ma","sequence":"additional","affiliation":[{"name":"Second Clinical College of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260223","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s12032-023-02231-2","article-title":"The evaluation of the anti-cancer effects of Anoectochilus roxburghii on hematological cancers in vitro.","volume":"41","author":"Gunes","year":"2023","journal-title":"Med Oncol"},{"key":"R2-20260223","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood.2023021221","article-title":"CAR T-cell therapy in multiple myeloma: mission accomplished?","volume":"143","author":"Rasche","year":"2023","journal-title":"Blood"},{"key":"R3-20260223","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20260223","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"R5-20260223","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-019-0819-1","article-title":"CAR-T \u201cthe living drugs,\u201d immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.","volume":"12","author":"Liu","year":"2019","journal-title":"J Hematol Oncol"},{"key":"R7-20260223","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1038\/s41467-023-40584-4","article-title":"Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level.","volume":"14","author":"John","year":"2023","journal-title":"Nat Commun"},{"key":"R8-20260223","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.coi.2012.06.004","article-title":"Engineered T cells for anti-cancer therapy.","volume":"24","author":"Turtle","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"R9-20260223","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells.","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol Rev"},{"key":"R10-20260223","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11899-013-0197-7","article-title":"Driving CAR-based T-cell therapy to success.","volume":"9","author":"Jena","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"R11-20260223","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1634\/theoncologist.2011-0380","article-title":"The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.","volume":"18","author":"Garrison","year":"2013","journal-title":"Oncologist"},{"key":"R12-20260223","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1158\/1078-0432.CCR-12-2422","article-title":"B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.","volume":"19","author":"Carpenter","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R13-20260223","doi-asserted-by":"crossref","first-page":"e2023066","DOI":"10.4084\/MJHID.2023.066","article-title":"CAR-T cell therapy in large B cell lymphoma.","volume":"15","author":"Testa","year":"2023","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"R14-20260223","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R15-20260223","first-page":"1068","article-title":"Progress of prognostic factors and treatment of extramedullary multiple myeloma.","volume":"50","author":"Chen","year":"2023","journal-title":"China Cancer Clinic"},{"key":"R16-20260223","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma.","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"R17-20260223","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach.","volume":"29","author":"Blad\u00e9","year":"2011","journal-title":"J Clin Oncol"},{"key":"R18-20260223","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2019.219139","article-title":"Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs.","volume":"105","author":"Montefusco","year":"2020","journal-title":"Haematologica"},{"key":"R19-20260223","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.leukres.2014.06.024","article-title":"First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.","volume":"38","author":"Muchtar","year":"2014","journal-title":"Leuk Res"},{"key":"R20-20260223","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study.","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"R21-20260223","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.3390\/cancers13194787","article-title":"Keeping myeloma in check: the past, present and future of immunotherapy in multiple myeloma.","volume":"13","author":"Ackley","year":"2021","journal-title":"Cancers"},{"key":"R22-20260223","first-page":"164","article-title":"Advances in the pathogenesis and treatment of multiple myeloma.","volume":"20","author":"Wang","year":"2023","journal-title":"China Med Innov"},{"key":"R23-20260223","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1200\/JCO.2018.77.8084","article-title":"T Cells genetically modified to express an Anti-B-Cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma.","volume":"36","author":"Brudno","year":"2018","journal-title":"J Clin Oncol"},{"key":"R24-20260223","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1073\/pnas.1819745116","article-title":"Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed\/refractory multiple myeloma.","volume":"116","author":"Xu","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"R25-20260223","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/16078454.2021.2005310","article-title":"Research progress on treatment of extramedullary multiple myeloma.","volume":"26","author":"Chen","year":"2021","journal-title":"Hematology"},{"key":"R26-20260223","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2018.05.009","article-title":"Antigenic targets of CAR T cell therapy. A retrospective view on clinical trials.","volume":"369","author":"Arabi","year":"2018","journal-title":"Exp Cell Res"},{"key":"R27-20260223","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"R28-20260223","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia.","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R29-20260223","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.","volume":"6","author":"Wang","year":"2018","journal-title":"Biomarker Res"},{"key":"R30-20260223","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-018-0653-x","article-title":"Cytokine release syndrome: grading, modeling, and new therapy.","volume":"11","author":"Liu","year":"2018","journal-title":"J Hematol Oncol"},{"key":"R31-20260223","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib.","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"R32-20260223","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights.","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"R33-20260223","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management.","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"R34-20260223","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment.","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T22:01:04Z","timestamp":1771884064000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,28]]},"references-count":33,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038541","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,28]]}}}